Quote
: |
刘志敏,彭清华,陈向东,蒲玟伶,胡卓瑜.逍遥散加减联合注射用鼠神经生长因子治疗原发性开角型青光眼的临床观察[J].湖南中医药大学学报英文版,2022,42(8):1365-1370.[Click to copy
] |
|
|
|
This paper
:Browser 1219times Download 609times |
逍遥散加减联合注射用鼠神经生长因子治疗原发性开角型青光眼的临床观察 |
刘志敏,彭清华,陈向东,蒲玟伶,胡卓瑜 |
(湖南中医药大学第一附属医院, 湖南 长沙 410007;湖南中医药大学, 湖南 长沙 410208;中医药防治眼耳鼻喉疾病湖南省重点实验室, 湖南 长沙 410208;湖南省中医药防治眼耳鼻喉疾病与视功能保护工程技术研究中心, 湖南 长沙 410208;中医药防治眼病与视功能保护湖南省工程研究中心, 湖南 长沙 410208) |
摘要: |
目的 观察逍遥散加减联合鼠神经生长因子对原发性开角型青光眼(primary open-angle glaucoma,POAG)患者的治疗效果。方法 将我院POAG患者56例(100只眼)随机分为对照组和观察组,各28例(50只眼)。观察组采用逍遥散加减联合鼠神经生长因子治疗,对照组单用注射用鼠神经生长因子治疗,两组均治疗8周。观察两组治疗前后视力、眼压、视野平均敏感度(value and mean sensitivity,MS)、视野平均缺损(mean deviation,MD)、图像视觉诱发电位(pattern visual evoked potential,P-VEP)、神经纤维层厚度变化。结果 治疗后,观察组视力提升、MS值增加、MD值减小,差异均有统计学意义(P<0.05);与对照组相比,观察组视力提升、MS值增加、MD值减小,差异均有统计学意义(P<0.05);两组治疗前后P-VEP、眼压、视盘和周边视网膜神经纤维层厚度比较,差异无统计学意义(P>0.05)。观察组总有效率高于对照组,差异有统计学意义(P<0.05)。结论 对于POAG患者,逍遥散加减联合注射用鼠神经生长因子能有效改善患者视力下降、视野缺损的状态,是中西医结合治疗POAG的临床有效途径,值得临床推广应用。 |
关键词: 原发性开角型青光眼 青光眼治疗 青风内障 逍遥散 鼠神经生长因子 临床观察 |
DOI:10.3969/j.issn.1674-070X.2022.08.022 |
Received:January 27, 2022 |
基金项目:湖南省教育厅科学研究项目(19A362);湖南省中医药管理局科研重点项目(201917);中医药防治眼耳鼻喉疾病湖南省重点实验室开放基金项目(2018YZD10)。 |
|
Clinical observation of modified Xiaoyao Powder combined with mouse nerve growth factor for injection in the treatment of primary open-angle glaucoma |
LIU Zhimin,PENG Qinghua,CHEN Xiangdong,PU Wenling,HU Zhuoyu |
(The First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha, Hunan 410007, China;Hunan University of Chinese Medicine, Changsha, Hunan 410208, China;Hunan Provincial Key Laboratory of Chinese Medicine for Prevention and Treatment of Eye, Ear, Nose and Throat Diseases, Changsha, Hunan 410208, China;Hunan Province Engineering Technology Research Center for Prevention and Treatment of Eye, Ear, Nose and Throat Diseases and Visual Function Protection with Chinese Medicine, Changsha, Hunan 410208, China;Hunan Engineering Research Center for Prevention and Treatment of Eye Diseases and Visual Function Protection with Chinese Medicine, Changsha, Hunan 410208, China) |
Abstract: |
Objective To observe the therapeutic effect of modified Xiaoyao Powder combined with mouse nerve growth factor on patients with primary open-angle glaucoma (POAG). Methods A total of 56 POAG patients (100 eyes) in our hospital were randomly divided into control group and observation group, with 28 cases (50 eyes) in each group. The observation group was treated with modified Xiaoyao Powder combined with mouse nerve growth factor, and the control group was treated with mouse nerve growth factor for injection alone. Both groups were treated for 8 weeks. The visual acuity, intraocular pressure, value and mean sensitivity (MS), mean deviation (MD), pattern visual evoked potential (P-VEP), and changes in nerve fiber layer thickness of the two groups before and after treatment were observed. Results After treatment, the visual acuity of the observation group improved, the MS value increased, and the MD value decreased, and the differences were statistically significant (P<0.05). Compared with the control group, the observation group had improved visual acuity, increased MS value, and decreased MD value, the differences were statistically significant (P<0.05); there was no significant difference in P-VEP, intraocular pressure, optic disc and peripheral retinal nerve fiber layer thickness between the two groups before and after treatment (P>0.05). The total effective rate in the observation group was higher than that in the control group, and the difference was statistically significant (P<0.05). Conclusion For POAG patients, modified Xiaoyao Powder combined with mouse nerve growth factor for injection can effectively improve the state of vision loss and visual field defect in patients, it is a clinically effective way to treat POAG with integrated traditional Chinese and western medicine, and it is worthy of clinical application. |
Key words: primary open-angle glaucoma glaucoma treatment Qingfeng cataract Xiaoyao Powder mouse nerve growth factor clinical observation |
|
二维码(扫一下试试看!) |
|
|
|
|